Innovation and imitati∞ πon,opportunity and chal♥♠↑lenge
Asia-Pacific Pharma IP Leader★δ& summit2019---14th-15×¥'th NOV, Beijing CHINAOn March 19, 2019, t₩↕he World Intellectual Property Organization (★★♣>WIPO) published its global intellectual<♠ property report 2018.Asian in₩∏novators filed more than half of their internati±'onal patent applications through WIPO for ♦γγthe first time in 2018, with signi¶✔ficant growth in China, India and South Koφ©₩rea, the report noted. As a tech¶>βnology-intensive industry, pharmaceu↓tical industry attaches gre↓β$Ωat importance to patent applic↓×ation and intellectu<φ'¶al property protection.In recent ✔ε≈↔years, the size of the☆♥ global pharmaceutical market has maintained a stααπeady growth, with China, South Korδ♠©γea, India and other emerging markets prese≥γnting a rapid growth momentum. Due t"γ₩o the different intellectual property polic✔ies of different countries, the strateg≠¶∑ic layout of global intellectual propertyπ¥✘, the differences of pharmaceutical ♠γ intellectual propert™'y policies of Asia-pacific countries, th∑ e patent review process, litigation procedα ∑ures and Generic drug pate₽₽>₽nt strategy have gradually become the hot spots o β♠f the pharmaceutical intellectu♦<δal property industry.In this context, t≥£↔♣he 2019 Asia-pacific Pharmaceutical IP Leade≈π r Summit will be held in Beijing&§→ on November 14-15, and will attract more tσ≥αhan 500 industry experts from domestic and f ★oreign pharmaceutical companies, biotechnology δε¶companies, governments, ass >₹↓ociations, law firms, inteδ←φllectual property agents and other cγ₽←ompanies to attend.Agenda €→γFramework:Section 1:Inter ♣>$pretation of Policy: Dev>×σβelopment of Pharmaceutical IP under the↕£♥ε New Legislative Landscape Section 2:Pharmaceuti§"↕cal R&D Innovation and IP Protection ≠ -- Global VisionSection 3:Case Sharing of αλPharmaceutical Patent Invalidity,₽" Infringement, LitigationSection 4:Opportunities ©¥¥"and challenges for generics companies under¶&σ♣ the new situation HOTSPOT:ü Me π£dical Policy Interpre™<≥tation under the Background of Patent Law Aφ£×¥mendmentü The innovation of Judici∞ ♠al Mechanism Promotes the Development of✘₽→ Pharmaceutical Intellectual Proper¥≥↔tyü Intellectual Propertγ'y Management Experienc♥"™e in Multinational Pharmaceutical Companies,♥÷≈ Patent Layout Strategy, Litigation€£≠→ Strategyü he Data Proπ<✔¥tection Regulations of Drug Tes≥ ε≈t—New Eraü Trade Secrets and Patent Lay←®out in the Medical Fieldü ↕€±₽ Establishing The Internal Intellectual Property ★←★®System under The New Legislative Landscapeü&♥"nbsp; Opportunities a≥☆nd Challenges of Phar®←maceutical Enterprises under ←¶÷Patent Term Compensation System--- Gl★₩₩♠obal Vision and Its Implications fφσor Chinaü Latest Changeδ≠↓βs in European Patent Appl±π₹'ication and Review Proced•εuresü Analysis oΩπf Hot Cases of Recent Patent Invalidationü&n$δbsp; The Procedure o₽©≤f American Pharmaceutical Patent litigatio ®n and its Enlightenment to Chinese Pharmac£™eutical Enterprises ü ±£>λApplication techniques and protect ¶ε↕ion strategies for European and American♦≠ biomedical patentsü Changes in standards f↑&or creative review of patentsü&nbs$'•p; European, AmericanΩ" and Japanese Medical Patent Examin₽♥£♦ation Cases and its implication ≤s for DomesticPharmaceuti €σcal Companiesü Recent Hot Paten γ™t Infringement Cases Analysisü The¥↓β Strategy of Indian Generic Drug Com©Ωγpanies in R&D and Pre-PAü•↔Ω How to avoid the Patent Trap in Ge&®≥φneric Drug Developmentü×'δ The Strategy of Generic Dru∏★®g Companies to Enter the European and American $'$↓Marketsü Patentability in E£¥urope, the United States and Chinaü P $∏÷atent litigation in Europeü Do∑ ↑←ubts around the Unified Patent Court (UPC) ag→£reement and Brexitü Second →¶medical use patentsComposition o Ω∞ f participants: Summ≥'it highlights:10+ Hot to¥λ'pic20+ Authoritat☆γive speech5 0+ Indus÷$♣σtry media4 0+ BIC110+pharma  ₩&±δ; company 500+專業(yè)參會≥€"(huì)嘉賓 &nbs€×$↕p; &nbs₹§σp; ♣$Professional participantsOfficial regist§γ₩ration and consultation channels:Contact:AnnPhoβδ×Ωne: 021-65650305Email:Marketing@zens₽₹βeegroup.comhttp://en.zensee©ε£∏group.com/p/510934/